Stock Analiz

Ligand Pharmaceuticals Inc. (LGND) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026

Summary

Ligand Pharmaceuticals’s revenue went from $109M in fiscal 2016 to $268M in fiscal 2025, growth of about 10.5% a year.

Net income in fiscal 2025 was $124M, a net margin of 46.4%; the best year in this period was 2019 with $629M.

Over the twelve months to September 30, 2026, revenue was $254M and net income $51M.

Free cash flow was $49M in fiscal 2025 and positive in 9 of the 10 years shown.

The diluted share count fell 3% over the period (buybacks).

Revenue, profit and cash flow by year

Revenue
2016: $109M162017: $141M172018: $251M182020: $164M202021: $242M212022: $196M222023: $131M232024: $167M242025: $268M25$268M
Net income
2016: -$2M162017: $13M172018: $143M182019: $629M192020: -$3M202021: $57M212022: -$33M222023: $52M232024: -$4M242025: $124M25$124M
Free cash flow
2016: $59M162017: $86M172018: $193M182019: -$32M192020: $50M202021: $70M212022: $120M222023: $46M232024: $95M242025: $49M25$49M
EPS (diluted)
2016: $-0.08162017: $0.53172018: $5.96182019: $31.85192020: $-0.18202021: $3.31212022: $-1.98222023: $2.94232024: $-0.22242025: $6.1325$6.13

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$254M$268M$167M$131M$196M$242M$164M—$251M$141M$109M
Gross profit————————$245M$136M$103M
Operating income$26M$41M-$23M$12M$3M$104M$38M$807M$164M$68M$44M
Net income$51M$124M-$4M$52M-$33M$57M-$3M$629M$143M$13M-$2M
EPS (diluted)$2.49$6.13$-0.22$2.94$-1.98$3.31$-0.18$31.85$5.96$0.53$-0.08
R&D$23M$81M$21M$25M$36M$32M$41M$56M$28M$27M$21M
Revenue growth—+60.4%+27.3%−33.1%−18.8%+47.7%——+78.2%+29.5%—

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$91M$49M$97M$50M$138M$79M$55M-$29M$194M$89M$61M
Capital spending-$405000-$452000-$2M-$4M-$18M-$9M-$4M-$3M-$887000-$2M-$2M
Free cash flow$91M$49M$95M$46M$120M$70M$50M-$32M$193M$86M$59M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks$60M$15M$0$0$0$0$78M$453M$123M$2M$4M
Stock-based pay$57M$47M$41M$26M$60M$39M$31M$25M$21M$25M$19M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$734M$256M$170M$212M$341M$411M$1.1B$718M$202M$141M
Debt—$451M$7M$6M$11M$338M$450M$650M$610M$225M$213M
Equity—$1.0B$830M$701M$597M$821M$710M$767M$561M$400M$341M
Total assets—$1.6B$942M$787M$763M$1.3B$1.4B$1.5B$1.3B$671M$602M
Shares (diluted)20M20M18M18M17M17M17M20M24M23M21M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin————————97.5%96.2%94.9%
Operating margin10.1%15.3%-13.5%9.1%1.6%43.0%22.9%—65.1%48.2%40.3%
Net margin20.3%46.4%-2.4%39.7%-17.0%23.7%-1.8%—57.0%8.9%-1.5%
FCF margin35.7%18.2%57.0%35.1%61.1%29.0%30.6%—76.8%61.2%54.0%
ROIC—2.2%-2.1%1.4%0.4%7.1%2.6%45.0%11.6%8.6%6.3%
ROE—12.2%-0.5%7.4%-5.6%7.0%-0.4%82.0%25.6%3.1%-0.5%

Frequently asked questions

What is Ligand Pharmaceuticals’s annual revenue?

$268M in fiscal 2025 and $254M over the twelve months to September 30, 2026.

How much profit does Ligand Pharmaceuticals make?

Net income was $124M in fiscal 2025 (net margin 46.4%).

Is Ligand Pharmaceuticals’s revenue growing?

Yes: revenue rose 60.4% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.